Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Grand View Research | PRODUCT CODE: 1405789

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1405789

Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2023 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Breast Cancer Core Needle Biopsy Market Growth & Trends:

The global breast cancer core needle biopsy market is expected to reach USD 1.15 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 4.9% from 2023 to 2030. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights:

  • By technology, the ultrasound-based breast biopsy segment dominated the market in 2022 due to its advantages over other biopsy technologies in terms of disease diagnosis. Further, increasing technological advancements are also expected to accelerate segment growth.
  • By end-use, hospitals & diagnostic laboratories segment held the largest market share in 2022, due to the increasing adoption of breast cancer biopsy instruments in hospitals along with growing demand for novel diagnostics technologies.
  • North America held a strong regional position in the market in 2022 owing to its highly developed healthcare infrastructure and presence of technologically advanced companies.
Show more
Product Code: GVR-4-68040-161-0

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Technology Segment
      • 1.1.1.2. End Use
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective 1
    • 1.4.2. Objective 2
    • 1.4.3. Objective 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Drivers
    • 3.4.1. Growing prevalence of breast cancer
    • 3.4.2. Advancement in imaging technologies and biopsy techniques
    • 3.4.3. Rising inclination towards minimally invasive procedures
  • 3.5. Market Restraint
    • 3.5.1. High cost of core needle biopsy procedures
    • 3.5.2. Limited expertise and training
  • 3.6. Industry Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Breast Cancer Core Needle Biopsy Market: Technology Movement Analysis
  • 4.2. MRI-Based Breast Biopsy
    • 4.2.1. MRI-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.3. Fermentation Ultrasound-Based Breast Biopsy
    • 4.3.1. Ultrasound-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.4. Mammography-Based (Stereotactic) Breast Biopsy
    • 4.4.1. Mammography-Based (Stereotactic) Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.5. CT-Based Breast Biopsy
    • 4.5.1. CT-Based Breast Biopsy Market, 2018 - 2030 (USD Million)
  • 4.6. Other Image-Based Breast Biopsy
    • 4.6.1. Other Image-Based Breast Biopsy Market, 2018 - 2030 (USD Million)

Chapter 5. End-use Business Analysis

  • 5.1. Breast Cancer Core Needle Biopsy Market: End-use Movement Analysis
  • 5.2. Hospitals & Diagnostic Laboratories
    • 5.2.1. Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
  • 5.3. Pharmaceutical & Biotechnology companies
    • 5.3.1. Pharmaceutical & Biotechnology Companies, Market, 2018 - 2030 (USD Million)
  • 5.4. Academic & Research Institutes
    • 5.4.1. Academic And Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Breast Cancer Core Needle Biopsy Market Share By Region, 2022 & 2030
  • 6.2. North America
    • 6.2.1. SWOT Analysis
    • 6.2.2. North America Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.2.3. U.S.
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Competitive Scenario
      • 6.2.3.4. Regulatory Framework
      • 6.2.3.5. U.S. Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.2.4. Canada
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Competitive Scenario
      • 6.2.4.4. Regulatory Framework
      • 6.2.4.5. Canada Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. SWOT Analysis
    • 6.3.2. Europe Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Competitive Scenario
      • 6.3.3.4. Regulatory Framework
      • 6.3.3.5. UK Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.4. Germany
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. Competitive Scenario
      • 6.3.4.4. Regulatory Framework
      • 6.3.4.5. Germany Breast Cancer Core Needle Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.5. France
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Competitive Scenario
      • 6.3.5.4. Regulatory Framework
      • 6.3.5.5. France Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Competitive Scenario
      • 6.3.6.4. Regulatory Framework
      • 6.3.6.5. Italy Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.7. Spain
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Competitive Scenario
      • 6.3.7.4. Regulatory Framework
      • 6.3.7.5. Spain Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.8. Denmark
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Competitive Scenario
      • 6.3.8.4. Regulatory Framework
      • 6.3.8.5. Denmark Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.9. Sweden
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Competitive Scenario
      • 6.3.9.4. Regulatory Framework
      • 6.3.9.5. Sweden Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.3.10. Norway
      • 6.3.10.1. Key Country Dynamics
      • 6.3.10.2. Target Disease Prevalence
      • 6.3.10.3. Competitive Scenario
      • 6.3.10.4. Regulatory Framework
      • 6.3.10.5. Norway Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. SWOT Analysis
    • 6.4.2. Asia Pacific Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Regulatory Framework
      • 6.4.3.5. Japan Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.4. China
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Competitive Scenario
      • 6.4.4.4. Regulatory Framework
      • 6.4.4.5. China Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.5. India
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Competitive Scenario
      • 6.4.5.4. Regulatory Framework
      • 6.4.5.5. India Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Competitive Scenario
      • 6.4.6.4. Regulatory Framework
      • 6.4.6.5. Australia Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. Competitive Scenario
      • 6.4.7.4. Regulatory Framework
      • 6.4.7.5. Thailand Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.4.8. South Korea
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Target Disease Prevalence
      • 6.4.8.3. Competitive Scenario
      • 6.4.8.4. Regulatory Framework
      • 6.4.8.5. South Korea Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. SWOT Analysis
    • 6.5.2. Latin America Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.3. Brazil
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Regulatory Framework
      • 6.5.3.5. Brazil Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Regulatory Framework
      • 6.5.4.5. Mexico Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.5.5. Argentina
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Regulatory Framework
      • 6.5.5.5. Argentina Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. SWOT Analysis
    • 6.6.2. MEA Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.3. South Africa
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Regulatory Framework
      • 6.6.3.5. South Africa Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.4. Saudi Arabia
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. Regulatory Framework
      • 6.6.4.5. Saudi Arabia Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.5. UAE
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Regulatory Framework
      • 6.6.5.5. UAE Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)
    • 6.6.6. Kuwait
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Regulatory Framework
      • 6.6.6.5. Kuwait Breast Cancer Core Needle Biopsy, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Share Analysis, 2022
  • 7.4. Company Profiles/Listing
    • 7.4.1. Intact Medical Corporation.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Ethicon Surgical Technologies
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Gallini SRL
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Leica Biosystems Nussloch GmbH
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Hologic, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Argon Medical Devices
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Encapsule Medical Devices LLC
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Cook Medical Incorporated
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Becton, Dickinson and Company
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. C.R. Bard, Inc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-161-0

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 3 Global breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 Global breast cancer core needle biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America breast cancer core needle biopsy market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 7 North America breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. breast cancer core needle biopsy market, by technology, 2018 - 2030 (USD Million)
  • Table 9 U.S. breast cancer core needle biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 11 Canada breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Europe breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 14 Europe breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 15 UK breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 16 UK breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Germany breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 18 Germany breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 19 France breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 20 France breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 21 Italy breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 22 Italy breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Spain breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 24 Spain breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Denmark breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 26 Denmark breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Sweden breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 28 Sweden breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Norway breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 30 Norway breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Japan breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 35 Japan breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 36 China breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 37 China breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 38 India breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 39 India breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Australia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 41 Australia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Thailand breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 43 Thailand breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 44 South Korea breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 45 South Korea breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Latin America breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 47 Latin America breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 48 Latin America breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Brazil breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 50 Brazil breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 51 Mexico breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 52 Mexico breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Argentina breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 54 Argentina breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa breast cancer core needle biopsy, by country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa breast cancer core needle biopsy, by technology, 2018-2030, (USD
  • Table 57 Middle East & Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 58 South Africa breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 59 South Africa breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 62 UAE breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 63 UAE breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Kuwait breast cancer core needle biopsy, by technology, 2018 - 2030 (USD Million)
  • Table 65 Kuwait breast cancer core needle biopsy, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 breast cancer core needle biopsy market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 13 Porter's Five Forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global breast cancer core needle biopsy market: Technology movement analysis
  • Fig. 16 Global breast cancer core needle biopsy market, for MRI-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 17 Global breast cancer core needle biopsy market, for ultrasound-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 18 Global breast cancer core needle biopsy market, for mammography-based (stereotactic) breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 19 Global breast cancer core needle biopsy market, for CT-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 20 Global breast cancer core needle biopsy market, for other image-based breast biopsy, 2018 - 2030 (USD Million)
  • Fig. 21 Global breast cancer core needle biopsy market: End use movement analysis
  • Fig. 22 Global breast cancer core needle biopsy market, for hospitals & diagnostic laboratories, 2018 - 2030 (USD Million)
  • Fig. 23 Global breast cancer core needle biopsy market, for pharmaceutical & biotechnology companies, 2018 - 2030 (USD Million)
  • Fig. 24 Global breast cancer core needle biopsy market, for academic & research institutes, 2018 - 2030 (USD Million)
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional outlook, 2022 & 2030
  • Fig. 27 Global breast cancer core needle biopsy market: Region movement analysis
  • Fig. 28 North America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 33 UK breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 34 France breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 42 China breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 43 India breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait breast cancer core needle biopsy market, 2018 - 2030 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!